Current and emerging treatment options for Graves’ hyperthyroidism

References

• BrentGAGraves’ DiseaseN Engl J Med20083582594260518550875
   PubMed Web of Science ®Google Scholar
• WiersingaWMBartalenaLEpidemiology and prevention of Graves’ ophthalmopathyThyroid20021285586012487767
   PubMed Web of Science ®Google Scholar
• VaidyaBWilliamsGRAbrahamPPearceSHSRadioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologistsClin Endocrinol (Oxf)20086881482017973939
   PubMed Web of Science ®Google Scholar
• NayakBHodakSPHyperthyroidismEndocrinol Metab Clin N Am200736617656
   PubMed Web of Science ®Google Scholar
• CooperDAntithyroid drugsN Engl J Med200535290591715745981
   PubMed Web of Science ®Google Scholar
• SonnetEMassartCGibassierJLongitudinal study of soluble intracellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves’ diseaseJ Endocrinol Invest19992243043510435852
   PubMed Web of Science ®Google Scholar
• TsatsoulisAVlachoyiannopoulosPGDalekosGNIncreased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugsEur J Clin Invest1995256546587498238
   PubMed Web of Science ®Google Scholar
• McGregorAMPetersonMMMclachlanSMCarbimazole and the autoimmune response in Graves’ diseaseN Engl J Med19803033023076247656
   PubMed Web of Science ®Google Scholar
• JanssonRDahlbergPAJohanssonHLindströmBIntrathyroidal concentrations of methimazole in patients with Graves’ diseaseJ Clin Endocrinol Metab1983571291326687892
   PubMed Web of Science ®Google Scholar
• ShiroozuAOkamuraKIkenoueHTreatment of hyperthyroidism with a single daily dose of methimazoleJ Clin Endocrinol Metab1986631251283011835
   PubMed Web of Science ®Google Scholar
• NicholasWCFischerRGStevensonRASingle daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidismSouth Med J1995889739767660219
   PubMed Web of Science ®Google Scholar
• BoumaDJKammerHSingle daily dose methimazole treatment of hyperthyroidismWest J Med198013213157376643
   PubMedGoogle Scholar
• HeCTHsiehATKuoSWComparison of single daily dose methimazole and propylthiouracil in the treatment of Graves’ hyperthyroidismClin Endocrinol (Oxf)20046067668115163329
   PubMed Web of Science ®Google Scholar
• BenkerGReinweinDKahalyGIs there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective studyClin Endocrinol (Oxf)1998494514579876342
   PubMed Web of Science ®Google Scholar
• EdmondsCJTellezMTreatment of Graves’ disease by carbimazole: high dose with thyroxine compared to titration doseEur J Endocrinol19941311201248075780
   PubMed Web of Science ®Google Scholar
• Goni-IriarteMJForga LlenasLIriarte BerioizARecurrence of Graves-Basedow disease: the influence of treatment schedule. [Spanish]Medicina Clinica199510411147877347
   PubMed Web of Science ®Google Scholar
• GrebeSKFeekCMFordHCA randomized trial of short-term treatment of Graves’ disease with high-dose carbimazole plus thyroxine versus low-dose carbimazoleClin Endocrinol (Oxf)1998485855929666870
   PubMed Web of Science ®Google Scholar
• JordeRYtre-ArneKStromerJSundsfjordJShort-term treatment of Graves’ disease with methimazole in high versus low dosesJ Intern Med19952381611657629484
   PubMed Web of Science ®Google Scholar
• LeclereJTreatment of Basedow disease with synthetic antithyroid drugs. Evaluation of the dose on the efficacy of the long term treatment. [French]Annales de Endocrinologie1994551114
   Google Scholar
• LucasASalinasIRiusFMedical therapy of Graves’ disease: does thyroxine prevent recurrence of hyperthyroidismJ Clin Endocrinol Metab199782241024139253309
   PubMed Web of Science ®Google Scholar
• McIverBRaePBeckettGWilkinsonEGoldAToftALack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drugN Engl J Med19963342202248531998
   PubMed Web of Science ®Google Scholar
• NedreboBGHolmPUhlvingSGraves’ disease: drug regimens and predictors of outcomeEur J Endocrinol200214758358912444889
   PubMed Web of Science ®Google Scholar
• RittmasterRSAbbottECDouglasREffect of methimazole, with or without L-thyroxine, on remission rates in Graves’ diseaseJ Clin Endocrinol Metab1998838148189506733
   PubMed Web of Science ®Google Scholar
• TuncelEErtturkEImamogluSEffects of Antithyroid drugs alone and plus L-Thyroxine on the relapse of Graves disease. [abstract]J Endocrinol Invest2000723
   Google Scholar
• WilsonRBuchananLFraserWDMcKillopJHThomsonJADo higher doses of carbimazole improve remission in Graves’ diseaseQ J Med199689381385
   Google Scholar
• AbrahamPAvenellAWatsonWAParkCMBevanJSA systematic review of drug therapy for Graves’ hyperthyroidismEur J Endocrinol200515348949816189168
   PubMed Web of Science ®Google Scholar
• HashizumeKIchikawaKSakuraiAAdministration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidismN Engl J Med19913249479531900575
   PubMed Web of Science ®Google Scholar
• GlinoerDde NayerPBexMBelgian Collaborative Study Group on Graves’ DiseaseEffects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized studyEur J Endocrinol200114447548311331213
   PubMed Web of Science ®Google Scholar
• HoermannRQuadbeckBRoggenbuckUfor Basedow Study GroupRelapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxineThyroid2002121119112812593726
   PubMed Web of Science ®Google Scholar
• MastorakosGDoufasAGMantzosEMantzosJKoutrasDAT4 but not T3 administration is associated with increased recurrence of Graves’ disease after successful medical therapyJ Endocrinol Invest20032697998414759070
   PubMed Web of Science ®Google Scholar
• AllannicHFauchetROrgiazziJAntithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment durationJ Clin Endocrinol Metab1990706756791689737
   PubMed Web of Science ®Google Scholar
• WeetmanAPPickerillAPWatsobPChatterjeeVKEdwardsOMTreatment of Graves’ disease with the block–replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapseQ J Med1994873373417913766
   PubMedGoogle Scholar
• García-MayorRVPáramoCLuna CanoRPérez MendezLFGalofréJCAndradeAAntithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remissionJ Endocrinol Invest1992158158201283984
   PubMed Web of Science ®Google Scholar
• MaugendreDGatelACampionLAntithyroid drugs and Graves’ disease – prospective randomized assessment of long-term treatmentClin Endocrinol (Oxf)19995012713210341866
   PubMed Web of Science ®Google Scholar
• TakataKKubotaSFukataSMethimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg dailyThyroid20091955956319445623
   PubMed Web of Science ®Google Scholar
• FukataSKumaKSugawaraMGranulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective studyThyroid199991293110037073
   PubMed Web of Science ®Google Scholar
• HarperLChinLDaykinJPropylthiouracil and carbimazole-associated antineutrophil cytoplasmatic antibodies (ANCA) in patients with Graves’ diseaseClin Endocrinol (Oxf)20046067167515163328
   PubMed Web of Science ®Google Scholar
• MandelSCooperDSThe use of antithyroid drugs in pregnancy and lactationJ Clin Endocrinol Metab2001862354235911397822
   PubMed Web of Science ®Google Scholar
• AbalovichMAminoNBarbourLAManagement of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice GuidelineJ Clin Endocrinol Metab200792Suppl 2S1S4717948378
   PubMedGoogle Scholar
• AziziFAtaieLHedayatiMMehrabiYShiekholeslamiFEffect of long-term continuous methimazole treatment of thyrotoxicosis: comparison with radioiodineEur J Endocrinol200515269570115879354
   PubMed Web of Science ®Google Scholar
• WalterRMBartleWRRectal administration of propylthiouracil in the treatment of Graves’ diseaseAm J Med19908869702294767
   PubMed Web of Science ®Google Scholar
• YeungSGoRBalasubramanyamARectal administration of iodide and propylthiouracil in the treatment of thyroid stormThyroid199554034058563481
   PubMed Web of Science ®Google Scholar
• NabilNMinerDJAmatrudaJMMethimazole: an alternative route of administrationJ Clin Endocrinol Metab1982541801817054215
   PubMed Web of Science ®Google Scholar
• JongjaroenprasertWAkarawutWChantasartDChailurkitLRajatanavinRRectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository formThyroid20021262763112193309
   PubMed Web of Science ®Google Scholar
• OsmanFGammageMDFranklynJAHyperthyroidism and cardiovascular morbidity and mortalityThyroid20021248348712165110
   PubMed Web of Science ®Google Scholar
• SawinCTBeckerDVRadioiodine and the treatment of hyperthyroidism: the early historyThyroid199771631769133679
   PubMed Web of Science ®Google Scholar
• WartofskyLGlinoerDSolomonBDifferences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan and the United StatesThyroid199111291351688014
   PubMedGoogle Scholar
• FranklynJAThe management of hyperthyroidismN Engl J Med1994330173117387910662
   PubMed Web of Science ®Google Scholar
• SridamaVMcCormickMKaplanELFauchetRDeGrootLJLong-term follow-up study of compensated low-dose 131I therapy for Graves’ diseaseN Engl J Med19843114264326205272
   PubMed Web of Science ®Google Scholar
• GooldenAWStewartJSLong-term results from graded low dose radioactive iodine therapy for thyrotoxicosisClin Endocrinol (Oxf)1986242172223708873
   PubMed Web of Science ®Google Scholar
• AlexanderEKLarsenPRHigh dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ diseaseJ Clin Endocrinol Metab2002871073107711889166
   PubMed Web of Science ®Google Scholar
• TamaiHKasagiKTakaichiYDevelopment of spontaneous hypothyroidism in patients with Graves’ disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patientsJ Clin Endocrinol Metab19896949532471711
   PubMed Web of Science ®Google Scholar
• PetersHFischerCBognerUReinersCSchleusenerHRadioiodine therapy of Graves’ hyperthyroidism: standard vs calculated 131iodine activity. Results from a prospective, randomized, multicentre studyEur J Clin Invest1995251861937781666
   PubMed Web of Science ®Google Scholar
• BurchHBSolomonBLCooperDSFergusonPWalpertNHowardRThe effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after 131I ablation for Graves’ diseaseJ Clin Endocrinol Metab20018673016302111443161
   PubMed Web of Science ®Google Scholar
• WalterMABrielMChrist-CrainMEffects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trialsBMJ200710 334:51417309884
   PubMedGoogle Scholar
• ImseisREVanmiddlesworthLMassieJDBushAJVanmiddlesworthNRPretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131in hyperthyroidismJ Clin Endocrinol Metab1998836856879467593
   PubMed Web of Science ®Google Scholar
• WilsonRMcKillopJHBuchananLMThe effect of carbimazole therapy on interleukin 2, interleukin 2 receptor and free radicalsAutoimmunity19908372129783
   PubMed Web of Science ®Google Scholar
• DunkelmannSKunstnerHNabaviEEberleinUGrothPSchumichenCLithium as an adjunct to radioiodine therapy in Graves’ disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?Nuclear-Medizin200645213218 quiz N51–N52.
   Web of Science ®Google Scholar
• BogazziFBartalenaLBrogioniSComparison of Radioiodine with Radioiodine plus Lithium in the treatment of Graves’ hyperthyroidismJ Clin Endocrinol Metab199984;2:49950310022407
   PubMed Web of Science ®Google Scholar
• JensenBEBonnemaSJHegedüsLGlucocorticoids do not influence the effect of radioiodine therapy in Graves’ diseaseEur J Endocrinol2005153152115994741
   PubMed Web of Science ®Google Scholar
• SilvaMNRubióIGRomãoRAdministration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitresClin Endocrinol (Oxf)20046030030815008994
   PubMed Web of Science ®Google Scholar
• DihnéMSchuierFJSchuierMHashimoto encephalopathy following iodine 131 (131I) radiotherapy of Graves diseaseArch Neurol20086528228318268203
   PubMedGoogle Scholar
• AcharyaSHAvenellAPhilipSBurrJBevanJSAbrahamPRadioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic reviewClin Endocrinol (Oxf)20086994395018429949
   PubMed Web of Science ®Google Scholar
• FranklynJASheppardMCMaisonneuvePThyroid function and mortality in patients treated for hyperthyroidismJAMA2005294718015998893
   PubMed Web of Science ®Google Scholar
• MetsoSJaatinenPHuhtalaHAuvinenAOksalaHSalmiJIncreased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidismJ Clin Endocrinol Metab2001922190219617374710
   PubMedGoogle Scholar
• HallPBergGBjelkengrenGCancer mortality after iodine-131 therapy for hyperthyroidismInt J Cancer1992508868901555888
   PubMed Web of Science ®Google Scholar
• FranklynJAMaisonneuvePSheppardMBetteridgeJBoylePCancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort studyLancet19993532111211510382695
   PubMed Web of Science ®Google Scholar
• RonEDoodyMMBeckerDVCancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study GroupJAMA19982803473559686552
   PubMed Web of Science ®Google Scholar
• ReadCHJrTanseyMJMendaYA 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patientsJ Clin Endocrinol Metab2004894229423315356012
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians, UKRadioiodine in the management of benign thyroid diseaseClinical guidelines. URL: http://www.rcplondon.ac.uk/pubs/brochure.aspx?e=208
   Google Scholar
• MaCKuangAXieJLiuGRadioiodine treatment for pediatric Graves’ diseaseCochrane Database Syst Rev20083CD00629418646146
   PubMed Web of Science ®Google Scholar
• SinzingerHAigingerPNeumannIHavlikERadiation alarm at an airport after radioiodine therapyNucl Med Commun200526676815604950
   PubMed Web of Science ®Google Scholar
• CoylePJMitchellJEThyroidectomy: is Lugol’s iodine necessaryAnn R Coll Surg Engl198264344345
   Web of Science ®Google Scholar
• RotiERobuschiGGardiniEComparison of methimazole, Methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves’ diseaseClin Endocrinol (Oxf)1988283053143168311
   PubMed Web of Science ®Google Scholar
• MercadoMMendoza-ZubietaVBautista-OsorioRTreatment of hyperthyroidism with a combination of methimazole and cholestyramineJ Clin Endocrinol Metab199681319131938784067
   PubMed Web of Science ®Google Scholar
• TsaiWCPeiDWangTThe effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves’ hyperthyroidismClin Endocrinol (Oxf)20056252152415853819
   PubMed Web of Science ®Google Scholar
• SalviMVannucchiGCampiITreatment of Graves’ disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open studyEur J Endocrinol2007156334017218723
   PubMed Web of Science ®Google Scholar
• El FassiDNielsenCHHasselbalchHCTreatment resistant severe active Graves’ ophthalmopathy successfully treated with B lymphocyte depletionThyroid20061670971016889501
   PubMed Web of Science ®Google Scholar
• El FassiDNielsenCHBonnemaSJHasselbalchHCHegedusLB lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: A controlled pilot studyJ Clin Endocrinol Metab2007921769177217284622
   PubMed Web of Science ®Google Scholar
• HeemstraKAToesRESepersJRituximab in relapsing Graves’ disease, a phase II studyEur J Endocrinol200815960961518628345
   PubMed Web of Science ®Google Scholar
• StalbergPSvenssonAHessmanOAkerstromGHellmanPSurgical Treatment of Graves’ Disease: Evidence-Based ApproachWorld J Surg2008321269127718327526
   PubMed Web of Science ®Google Scholar
• PalitTKMillerCCIIIMiltenburgDMThe efficacy of thyroidectomy for Graves’ disease: a meta-analysisJ Surg Res20009016116510792958
   PubMed Web of Science ®Google Scholar
• MenconiFMarinoMPincheraAEffects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoidsJ Clin Endocrinol Metab2007921653165817299076
   PubMed Web of Science ®Google Scholar
• XiaoHZhuangWWangSArterial embolization: A nover approach to thyroid ablative therapy for Graves’ diseaseJ Clin Endocrinol Metab2002873583358912161479
   PubMed Web of Science ®Google Scholar
• PatelNNAbrahamPBuscombeJVanderpumpMPJThe Cost Effectiveness of Treatment Modalities for Thyrotoxicosis in a UK CentreThyroid20061659359816839261
   PubMed Web of Science ®Google Scholar